Breaking Ground: Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial for QTORIN™ Rapamycin in Cutaneous Venous Malformations

Palvella Therapeutics, Inc. has announced a key milestone in the development of therapies for rare genetic skin diseases: the completion of enrollment in its Phase 2 TOIVA trial of QTORIN™…

Continue Reading Breaking Ground: Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial for QTORIN™ Rapamycin in Cutaneous Venous Malformations